Aberrant DNA methylation in ovarian cancer

Is there an epigenetic predisposition to drug response?

Susan H. Wei, Robert Brown, Hui-ming Huang

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Epigenetic regulation of gene expression has been observed in a variety of tumor types. We have used microarray technology to evaluate the predisposition of drug response by aberrant methylation in ovarian cancer. Results indicate that loss of gene activity due to hypermethylation potentially confers a predisposition in certain cancer types and is an early event in disease progression. Methylation profiles of ovarian cancer might be useful for early cancer detection and prediction of chemotherapy outcome in a clinical context.

Original languageEnglish (US)
Pages (from-to)243-250
Number of pages8
JournalAnnals of the New York Academy of Sciences
Volume983
StatePublished - Mar 2003
Externally publishedYes

Fingerprint

Methylation
DNA Methylation
Epigenomics
Ovarian Neoplasms
Chemotherapy
Gene Expression Regulation
Microarrays
Early Detection of Cancer
Gene expression
Pharmaceutical Preparations
Disease Progression
Tumors
Neoplasms
Genes
Technology
Drug Therapy
Predisposition
Epigenetics
Drugs
Cancer

Keywords

  • And mismatch repair
  • Chemotherapy
  • Cisplatin
  • DNA methylation
  • Drug-resistance
  • High-throughput
  • Microarray

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Aberrant DNA methylation in ovarian cancer : Is there an epigenetic predisposition to drug response? / Wei, Susan H.; Brown, Robert; Huang, Hui-ming.

In: Annals of the New York Academy of Sciences, Vol. 983, 03.2003, p. 243-250.

Research output: Contribution to journalArticle

@article{839e570b995142ddad04498f06f39838,
title = "Aberrant DNA methylation in ovarian cancer: Is there an epigenetic predisposition to drug response?",
abstract = "Epigenetic regulation of gene expression has been observed in a variety of tumor types. We have used microarray technology to evaluate the predisposition of drug response by aberrant methylation in ovarian cancer. Results indicate that loss of gene activity due to hypermethylation potentially confers a predisposition in certain cancer types and is an early event in disease progression. Methylation profiles of ovarian cancer might be useful for early cancer detection and prediction of chemotherapy outcome in a clinical context.",
keywords = "And mismatch repair, Chemotherapy, Cisplatin, DNA methylation, Drug-resistance, High-throughput, Microarray",
author = "Wei, {Susan H.} and Robert Brown and Hui-ming Huang",
year = "2003",
month = "3",
language = "English (US)",
volume = "983",
pages = "243--250",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Aberrant DNA methylation in ovarian cancer

T2 - Is there an epigenetic predisposition to drug response?

AU - Wei, Susan H.

AU - Brown, Robert

AU - Huang, Hui-ming

PY - 2003/3

Y1 - 2003/3

N2 - Epigenetic regulation of gene expression has been observed in a variety of tumor types. We have used microarray technology to evaluate the predisposition of drug response by aberrant methylation in ovarian cancer. Results indicate that loss of gene activity due to hypermethylation potentially confers a predisposition in certain cancer types and is an early event in disease progression. Methylation profiles of ovarian cancer might be useful for early cancer detection and prediction of chemotherapy outcome in a clinical context.

AB - Epigenetic regulation of gene expression has been observed in a variety of tumor types. We have used microarray technology to evaluate the predisposition of drug response by aberrant methylation in ovarian cancer. Results indicate that loss of gene activity due to hypermethylation potentially confers a predisposition in certain cancer types and is an early event in disease progression. Methylation profiles of ovarian cancer might be useful for early cancer detection and prediction of chemotherapy outcome in a clinical context.

KW - And mismatch repair

KW - Chemotherapy

KW - Cisplatin

KW - DNA methylation

KW - Drug-resistance

KW - High-throughput

KW - Microarray

UR - http://www.scopus.com/inward/record.url?scp=0345701519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345701519&partnerID=8YFLogxK

M3 - Article

VL - 983

SP - 243

EP - 250

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -